Last updated: August 9, 2026
Amlodipine besylate and atorvastatin calcium is an established fixed-dose combination for hypertension and dyslipidemia. The commercial opportunity is no longer based on basic molecule protection. It is based on manufacturing efficiency, dose flexibility, stability control, adherence, market access, and differentiated oral delivery.
The highest-value formulation strategy is a robust immediate-release tablet platform that controls low-dose amlodipine distribution, protects atorvastatin from degradation, and supports multiple strength ratios without creating excessive inventory or process complexity. Separate API granulation, co-processed excipients, bilayer tablets, orally disintegrating formats, and regional polypill products offer additional opportunities.
What is the commercial product profile of amlodipine and atorvastatin?
Amlodipine besylate is a dihydropyridine calcium-channel blocker. Atorvastatin calcium is an HMG-CoA reductase inhibitor. The combination addresses two major cardiovascular risk factors through a single oral dosage form.
The reference product is Caduet, originally marketed by Pfizer. FDA-approved strengths combine amlodipine at 2.5 mg, 5 mg, or 10 mg with atorvastatin at 10 mg, 20 mg, 40 mg, or 80 mg, subject to the approved strength matrix and labeling restrictions.[1]
| Attribute |
Amlodipine besylate |
Atorvastatin calcium |
| Therapeutic class |
Calcium-channel blocker |
Statin |
| Primary use |
Hypertension and coronary artery disease |
Hypercholesterolemia and cardiovascular risk reduction |
| Typical dose range in combination |
2.5-10 mg |
10-80 mg |
| Relative formulation issue |
Very low dose and blend uniformity |
Higher dose, poor aqueous solubility, solid-state and degradation control |
| Dosage-form opportunity |
Immediate release, ODT, multiparticulate |
Immediate release, separate granulation, amorphous or particle-engineered material |
| Regulatory pathway for generic |
ANDA, if pharmaceutical equivalence is demonstrated |
ANDA, if pharmaceutical equivalence and bioequivalence are demonstrated |
The product is a small-molecule combination. Biosimilar competition is not relevant. Competitive entry occurs through abbreviated new drug applications, national generic pathways, line extensions, and fixed-dose cardiovascular combinations.
What excipients are most suitable for the combination tablet?
A conventional immediate-release formulation can use a conventional direct-compression or wet-granulation system. The formulation must manage the very low amlodipine load while maintaining atorvastatin dissolution and chemical stability.
| Formulation function |
Candidate excipients |
Strategic purpose |
| Diluent |
Microcrystalline cellulose, dibasic calcium phosphate, lactose monohydrate, mannitol |
Controls tablet weight, compressibility, and cost |
| Binder |
Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose |
Improves granule strength and content uniformity |
| Disintegrant |
Croscarmellose sodium, crospovidone, sodium starch glycolate |
Supports rapid tablet breakup |
| Glidant |
Colloidal silicon dioxide |
Improves flow and reduces segregation |
| Lubricant |
Magnesium stearate, sodium stearyl fumarate |
Reduces sticking and ejection force |
| Wetting or dissolution aid |
Poloxamer, sodium lauryl sulfate, selected surfactant systems |
May improve atorvastatin wetting |
| Film coat |
Hypromellose, polyvinyl alcohol, titanium dioxide, talc, polyethylene glycol |
Protects the core and supports product identification |
| Taste-masking system |
Mannitol, sucralose, flavor systems, polymeric coating |
Relevant to ODT and pediatric development |
Excipient selection must remain within the inactive-ingredient precedents established for the intended route, dose, and dosage form. FDA’s Inactive Ingredient Database is the principal US screening tool, but prior use does not eliminate the need to justify quantity, safety, manufacturing function, and compatibility.[2]
Why microcrystalline cellulose is commercially attractive
Microcrystalline cellulose is a strong platform excipient because it supports direct compression, accommodates a wide range of tablet weights, and is available from multiple suppliers. It can reduce process steps compared with wet granulation.
Its limitations are equally important. Low-dose amlodipine can segregate from a predominantly cellulose-based blend if particle size, density, or loading order is poorly controlled. A formulation that uses direct compression should therefore include blend-uniformity controls, engineered API particle size, controlled addition of the amlodipine premix, and validated sampling plans.
When is dibasic calcium phosphate preferable?
Dibasic calcium phosphate can improve flow, hardness, and low-moisture processing. It is useful when a dry, robust tablet process is preferred. Its density can increase segregation risk against low-dose amlodipine, and its abrasive character can affect tooling and blend behavior. It should be evaluated with the selected atorvastatin calcium grade rather than treated as an interchangeable diluent.
What role do surfactants and wetting agents play?
Atorvastatin calcium has limited aqueous solubility. A surfactant or wetting aid can improve dissolution, but excessive surfactant may increase tablet sensitivity, affect disintegration, or create compatibility problems. Sodium lauryl sulfate and poloxamers may be useful screening candidates, but the final selection should be driven by dissolution across pH conditions, impurity formation, and long-term stability.
How should the formulation manage API compatibility?
The main technical risk is the coexistence of a low-dose, blend-sensitive amlodipine component with a higher-dose, poorly soluble atorvastatin component.
Amlodipine-specific risks
Amlodipine is used at a low dose relative to the tablet mass. The main risks are:
- Blend segregation and content-uniformity failure
- Sensitivity to light and environmental stress
- Over-lubrication that slows disintegration
- Loss of dose accuracy across multiple strength ratios
Amlodipine should be evaluated in a premix or granulated fraction before final blending. A premix with a geometrically matched diluent can improve distribution. The commercial process should limit transfers and avoid large differences in particle density.
Atorvastatin-specific risks
Atorvastatin calcium creates a different set of risks:
- Low aqueous solubility
- Dependence of dissolution on particle size and wetting
- Potential degradation under unsuitable pH, moisture, light, or thermal conditions
- Possible lactonization or related impurity formation during development and storage
The formulation should use a controlled API particle-size specification and should evaluate both crystalline form and surface characteristics. The product should be tested for assay, related substances, dissolution, water activity, and stability under ICH conditions.[3]
Should the APIs be physically separated?
Separate granulation or a bilayer architecture can reduce direct contact between the two APIs and create independent optimization spaces. This approach is most attractive when:
- A single blend fails content uniformity.
- The APIs show incompatibility in accelerated stability.
- The target product has a high atorvastatin dose and a very low amlodipine dose.
- The sponsor wants to support future ODT, multilayer, or modified-release extensions.
The cost is higher tooling, more complex scale-up, greater weight-control risk, and a more demanding validation package. For a low-cost generic, a single-layer platform is preferable if it meets quality targets.
What formulation patents could protect a new product?
The active ingredients and basic fixed-dose concept are mature. New patent value would more likely come from formulation and process claims.
| Patent category |
Potential claim subject |
Commercial strength |
| Composition |
Defined excipient ratios, particle-size ranges, or granule architecture |
Moderate if tied to unexpected performance |
| Bilayer tablet |
Separate amlodipine and atorvastatin layers with defined release profiles |
Moderate to strong if stability or bioavailability improves |
| ODT |
Rapid disintegration, taste masking, and dose uniformity |
Moderate |
| Process |
Controlled premix, continuous blending, or low-shear granulation |
Moderate, but difficult to enforce against an undisclosed process |
| Stability |
Packaging and formulation system that reduces impurities |
Moderate if supported by comparative data |
| Method of use |
Improved adherence, selected cardiovascular population, or dosing regimen |
Variable and jurisdiction-dependent |
| Combination product |
New strength matrix or synchronized dosing program |
Usually weaker unless clinically differentiated |
A patent should claim measurable technical features, not merely the use of familiar excipients. A broad claim to microcrystalline cellulose, croscarmellose sodium, and magnesium stearate would face substantial prior-art risk. Stronger positions may arise from a defined particle-size distribution, a separated API architecture, a dissolution profile, a stability result, or a manufacturing parameter linked to product performance.
What is the Orange Book and generic-entry status?
Caduet is an FDA-approved small-molecule fixed-dose combination. Its core commercial exclusivity has been overtaken by generic competition in the United States. FDA Orange Book entries, listed patents, pediatric extensions, and approved generic strengths should be checked for the specific product and strength under review.[4]
The relevant generic issues are:
- Pharmaceutical equivalence of the same active ingredients and strength
- Bioequivalence for the immediate-release tablet
- Same dosage form and route of administration
- Paragraph IV certifications against any remaining listed patents
- Labeling carve-outs for protected methods of use
- Strength-specific approval and supply economics
A generic applicant may challenge listed patents through a Paragraph IV certification. The 30-month stay mechanism applies when the patent holder files a timely infringement action after receiving notice, subject to the statutory framework and later court or FDA events.[5]
For a new formulation with a different dosage form, delivery profile, or clinical use, an ANDA may not be available. The sponsor may need a 505(b)(2) application or a full new drug application, depending on how substantially the product differs from the reference product.[6]
When does amlodipine and atorvastatin lose exclusivity?
The basic combination has already entered the post-exclusivity market in major jurisdictions. The practical question is no longer the expiration of the original combination estate. It is whether a sponsor can obtain enforceable protection around a differentiated formulation or whether generic pricing has already compressed the opportunity.
| Exclusivity layer |
Current commercial relevance |
| Active-ingredient patents |
Low for standard amlodipine and atorvastatin products |
| Original combination patents |
Historical importance; current status depends on jurisdiction and specific listing |
| Regulatory exclusivity |
Generally no material barrier for an established generic combination |
| Formulation patents |
Potentially relevant for ODT, bilayer, stability, or manufacturing innovations |
| Method-of-use patents |
Relevant only for narrowly defined, enforceable indications or dosing methods |
| Orphan exclusivity |
Not generally applicable |
| Pediatric exclusivity |
Must be checked against the historical Orange Book record |
A commercial diligence report should distinguish patent expiration from regulatory market exclusivity. They are separate legal concepts and can produce different entry dates.
What commercial opportunities exist for excipient suppliers?
Excipient suppliers can compete through performance, not only price. The most attractive opportunities are:
Co-processed direct-compression systems
A co-processed filler-binder-disintegrant can improve flow, compactibility, and scale-up. The value proposition is strongest when the system reduces granulation, improves low-dose uniformity, or supports continuous manufacturing.
Low-moisture and low-peroxide excipients
Excipient grades with controlled moisture, low peroxide content, and defined particle-size distributions may reduce atorvastatin impurity formation and improve shelf life. Suppliers can support this positioning with extractables, elemental impurities, nitrosamine-risk, and stability data.
ODT-grade platforms
Mannitol-based systems, optimized crospovidone, and taste-masking polymers can support orally disintegrating amlodipine-atorvastatin products. The key commercial hurdles are atorvastatin taste, tablet friability, moisture sensitivity, and acceptable tablet weight.
Granulation and continuous-processing systems
Excipients engineered for continuous blending or dry granulation can reduce manufacturing variability. This is especially relevant for a low-dose component such as amlodipine.
Regional excipient substitution
Many generic manufacturers need alternatives to expensive imported excipients. Suppliers that can qualify equivalent grades with robust documentation can capture business in India, Southeast Asia, Latin America, and other price-sensitive markets.
How does this product compare with competing cardiovascular combinations?
Amlodipine-atorvastatin competes with separate prescriptions, statin-plus-antihypertensive polypills, and other fixed-dose combinations.
| Product approach |
Advantage |
Limitation |
| Separate amlodipine and atorvastatin tablets |
Maximum dose flexibility |
Higher pill burden |
| Amlodipine-atorvastatin fixed-dose tablet |
Simplified regimen and established clinical use |
Limited strength combinations |
| Amlodipine plus another statin |
May offer broader statin positioning |
Different clinical and regulatory profile |
| Multicomponent cardiovascular polypill |
Greater adherence potential |
More complex regulatory, stability, and patent requirements |
| ODT combination |
Useful for swallowing difficulty and adherence |
Higher excipient, taste, and packaging burden |
The strongest commercial case is in patients who already require both therapies and are likely to benefit from reduced pill burden. A new product should not rely solely on the existence of two active ingredients. It should demonstrate a practical advantage in adherence, dosing convenience, cost, or access.
What generic launch risks exist?
Generic launch risk is primarily economic and operational:
- Multiple suppliers can compress prices rapidly.
- The high atorvastatin strengths may have lower volume but greater API and tablet-weight requirements.
- A broad strength matrix increases inventory and validation costs.
- A formulation that requires separate granulation may lose cost competitiveness.
- Substitution rules may vary by country and may not treat the combination as interchangeable with separate tablets.
- Supply interruptions for atorvastatin API or specialized excipients can affect multiple strengths simultaneously.
Manufacturing IP can create an additional barrier, but process patents are difficult to detect when the process is performed privately. Formulation claims with observable product characteristics are more commercially relevant for enforcement.
Key Takeaways
- The commercial opportunity is based on differentiated formulation, manufacturing efficiency, and adherence rather than basic molecule exclusivity.
- A single-layer immediate-release tablet is the lowest-cost platform if it meets blend uniformity, dissolution, and stability requirements.
- Separate API granulation or bilayer technology is justified when low-dose amlodipine distribution or API compatibility becomes a critical failure mode.
- Microcrystalline cellulose, dibasic calcium phosphate, croscarmellose sodium, crospovidone, povidone, colloidal silicon dioxide, and magnesium stearate are logical development candidates.
- Excipient innovation is strongest when linked to low moisture, low peroxide, improved dissolution, direct compression, or continuous manufacturing.
- Biosimilar risk does not apply. Competition comes from ANDA and other small-molecule generic pathways.
- New patent value is most likely in ODT, bilayer, stability, particle engineering, defined dissolution, and manufacturing claims.
- The FDA Orange Book remains the controlling source for current US patent listings and regulatory status.
FAQs
Can amlodipine besylate and atorvastatin calcium be formulated in one tablet?
Yes. The combination is established as an immediate-release tablet. Development must control low-dose amlodipine uniformity, atorvastatin dissolution, chemical stability, and the selected strength matrix.
Is a bilayer tablet commercially justified?
It can be justified when a common blend produces segregation, incompatibility, or dissolution failures. For a low-cost generic, the additional manufacturing complexity must produce a measurable quality or commercial benefit.
Which excipient is best for atorvastatin dissolution?
No single excipient is universally optimal. Wetting agents, particle-size control, porous carriers, and disintegrant selection should be screened together against dissolution and impurity results.
Can a new excipient combination obtain patent protection?
Yes, but a patent generally requires more than a list of known excipients. The claims should connect defined composition or process parameters to an unexpected stability, dissolution, uniformity, or manufacturing result.
Is an orally disintegrating version likely to require a 505(b)(2) application?
Usually, a materially different dosage form may require a 505(b)(2) pathway rather than an ANDA, depending on FDA’s assessment of pharmaceutical equivalence, formulation differences, and the evidentiary bridge to the reference product.
References
-
U.S. Food and Drug Administration. (2023). Caduet: Amlodipine besylate and atorvastatin calcium prescribing information. FDA/DailyMed.
-
U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
-
International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).
-
U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.
